Single Nucleotide Polymorphism (SNP) Panels and Risk Assessment in Women Undergoing Mammography

03:40 EDT 26th October 2014 | BioPortfolio

Summary

This protocol compares use of single nucleotide polymorphism panels to common risk assessment models. Women undergoing screening mammography or breast biopsy due to BIRADS Category 4 lesion will be asked to provide buccal swabs and health information used to complete each risk model. These risk models will be compared to see whether either improves the positive predictive value of breast biopsy for BIRADS4 lesions. Subjects undergoing biopsy will be followed to examine cancer outcomes.

Description

Calculating the risk that a woman will develop breast cancer in her lifetime can lead to decreased mortality rates as a result of increased screening and prevention methods when a person is known to be at high risk. Though there are several risk assessment models that are commonly used, it is important to continue to improve the process of calculating risk. Several genetic markers have been noted to potentially indicate risk of developing breast cancer. New tests, called SNP panels, can detect some of these genetic markers. This study aims to use both these SNP panels and the commonly used risk models to calculate risk and examine outcomes in women coming in to do screening mammography. This study will enroll women between the ages of 40-65 who are undergoing screening mammography (n=600), in addition to women with BIRADS category 4 mammogram readings who are about to undergo biopsy (n=600), all with no personal history of breast or ovarian cancer, ductal carcinoma in situ (DCIS), mantle radiation, or known BRCA 1/2/mutation in self or family members. The participants will only be expected rto provide consent, swabs of the inside of the cheek of her mouth, and baseline questionnaire answers that will allow for a risk assessment to be performed.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Conditions

Mammography

Location

Abramson Cancer Center of the University of Pennsylvania
Philadelphia
Pennsylvania
United States
19104

Status

Recruiting

Source

Abramson Cancer Center of the University of Pennsylvania

Results (where available)

View Results

Links

Clinical Trials [55 Associated Clinical Trials listed on BioPortfolio]

Positron Emission Mammography and Standard Mammography in Women With Dense Breast Tissue or Who Are at High Risk of Breast Cancer

RATIONALE: Screening tests may help doctors find cancer cells early and plan better treatment for breast cancer. It is not yet known whether positron emission mammography is more effective...

Computed Tomography Laser Mammography Breast Imaging Device

The purpose of this study is to evaluate the sensitivity and specificity of the CTLM system when used adjunctively with mammography compared to mammography alone in the heterogeneously and...

Visibility of Lesion Characteristics With Phase Contrast Mammography

To determine if diagnostic phase contrast mammography (PCM) will provide improved image detail in assessing lesion characteristics when compared to diagnostic x-ray mammography (XM).

Earlier Breast Cancer Detection Using Automated Whole Breast Ultrasound With Mammography, Including Cost Comparisons

The purpose of this study is to determine whether addition of automated whole breast ultrasound to the usual screening mammography in a population of asymptomatic women with mammographical...

Computed Radiography (CR) Data Collection for Mammography Computer Aided Detection (CAD)

The objective of this study is to collect an image library of diagnostic digital mammograms using the Carestream CR mammography system from patients who have histological-conformed breast ...

PubMed Articles [134 Associated PubMed Articles listed on BioPortfolio]

Diagnostic performance of dual-energy contrast-enhanced subtracted mammography in dense breasts compared to mammography alone: interobserver blind-reading analysis.

To analyse the accuracy of dual-energy contrast-enhanced spectral mammography in dense breasts in comparison with contrast-enhanced subtracted mammography (CESM) and conventional mammography (Mx).

Comparison of standard mammography with digital mammography and digital infrared thermal imaging for breast cancer screening.

Breast cancer is the most common malignancy in women. Screen-film mammography (SFM) has been considered the gold standard for breast cancer screening and detection. Despite its recognized value in det...

Breast cancer screening programmes: Challenging the coexistence with opportunistic mammography.

This study investigated predictive factors of women's participation in organized mammography screening (OrgMS) and/or opportunistic mammography screening (OppMS) when the two screening modes coexist.

Radiation Exposure of Contrast-Enhanced Spectral Mammography Compared With Full-Field Digital Mammography.

Contrast-enhanced spectral mammography (CESM) shows promising initial results but comes at the cost of increased dose as compared with full-field digital mammography (FFDM). We aimed to quantitatively...

Should we screen BRCA1 mutation carriers only with MRI? A multicenter study.

BRCA1 mutation carriers are offered screening with MRI and mammography. Aim of the study was to investigate the additional value of digital mammography over MRI screening. BRCA1 mutation carriers, who...

Medical and Biotech [MESH] Definitions

Radiographic examination of the breast.

More From BioPortfolio on "Single Nucleotide Polymorphism (SNP) Panels and Risk Assessment in Women Undergoing Mammography"

Search BioPortfolio:
Loading
Advertisement

Relevant Topics

Women's Health
Latest News Clinical Trials Research Drugs Reports Corporate
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Breast Cancer
Latest News Clinical Trials Research Drugs Reports Corporate
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...

Advertisement